Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Prostatecancerscreening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. OBJECTIVE: To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostatecancer. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018 (...) . ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSAscreening with usual care in men without a diagnosis of prostatecancer. DATA EXTRACTION: At least two reviewers screened studies, extracted data, and assessed the quality of eligible studies. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including selection of outcomes important to patients. We used a random effects model to obtain
Prostatecancerscreening Top results for prostatecancerscreening - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostatecancerscreening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection
Screening for ProstateCancer: US Preventive Services Task Force Recommendation Statement. Importance: In the United States, the lifetime risk of being diagnosed with prostatecancer is approximately 13%, and the lifetime risk of dying of prostatecancer is 2.5%. The median age of death from prostatecancer is 80 years. Many men with prostatecancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history (...) of prostatecancer have an increased risk of prostatecancer compared with other men. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostatecancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostatecancer and subsequent treatment of screen-detected prostatecancer. The USPSTF also commissioned a review of existing decision analysis models
Prostate-Specific Antigen-Based Screening for ProstateCancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Importance: Prostatecancer is the second leading cause of cancer death among US men. Objective: To systematically review evidence on prostate-specific antigen (PSA)-based prostatecancerscreening, treatments for localized prostatecancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force. Data Sources: Searches of PubMed (...) Extraction and Synthesis: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. Main Outcomes and Measures: Prostatecancer and all-cause mortality; false-positive screening results, biopsy complications, overdiagnosis; adverse effects of active treatments. Random-effects meta-analyses were conducted for treatment harms. Results: Sixty-three studies in 104 publications were included (N = 1 904 950). Randomization to PSAscreening was
ProstateCancer: Screening USPSTF Final ProstateScreening Recommendations Text Size: ProstateCancerScreening Final Recommendation Providing clinicians and patients with important information to help guide decisions about prostatecancerscreening. The U.S. Preventive Services Task Force (USPSTF or Task Force) has reviewed the evidence on PSA-based screening for prostatecancer and published its final recommendation. The Task Force is deeply committed to a clear and transparent recommendation (...) development process and this final recommendation was informed by comments we received on our draft recommendation from experts, stakeholders and the public. The Task Force recommends men ages 55 to 69 make an individual decision about prostatecancerscreening with their clinician. The Task Force recommends against routine screening for men age 70 and older. Final Recommendations Men ages 55–69 For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)–based screening
Effect of a Low-Intensity PSA-Based Screening Intervention on ProstateCancer Mortality: The CAP Randomized Clinical Trial. Importance: Prostatecancerscreening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective: To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostatecancer-specific mortality. Design, Setting (...) -specific mortality at a median follow-up of 10 years. Prespecified secondary outcomes: diagnostic cancer stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostatecancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSAscreening clinic. Results: Among 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included
Polygenic hazard score to guide screening for aggressive prostatecancer: development and validation in large scale cohorts. OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostatecancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate (...) their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSAscreening data. The hazard score was calculated
Screening for ProstateCancer* Screening for ProstateCancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for ProstateCancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostatecancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr
Reconciling the Effects of Screening on ProstateCancer Mortality in the ERSPC and PLCO Trials. Background: The ERSPC (European Randomized Study of Screening for ProstateCancer) found that screening reduced prostatecancer mortality, but the PLCO (Prostate, Lung, Colorectal, and Ovarian CancerScreening Trial) found no reduction. Objective: To evaluate whether effects of screening on prostatecancer mortality relative to no screening differed between the ERSPC and PLCO. Design: Cox regression (...) of prostatecancer death in each trial group, adjusted for age and trial. Extended analyses accounted for increased incidence due to screening and diagnostic work-up in each group via mean lead times (MLTs), which were estimated empirically and using analytic or microsimulation models. Setting: Randomized controlled trials in Europe and the United States. Participants: Men aged 55 to 69 (ERSPC) or 55 to 74 (PLCO) years at randomization. Intervention: Prostatecancerscreening. Measurements: Prostate
EAU-ESTRO-SIOG Guidelines on ProstateCancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent 27568654 2016 08 29 2017 03 04 1873-7560 71 4 2017 Apr European urology Eur. Urol. EAU-ESTRO-SIOG Guidelines on ProstateCancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. 618-629 S0302-2838(16)30470-5 10.1016/j.eururo.2016.08.003 To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy (...) & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostatecancer (PCa). The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence. BRCA2 mutations have been added as risk factors for early and aggressive disease
Psychological Predictors of ProstateCancerScreening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy 27761205 2018 11 13 2008-2398 9 4 2016 Aug Iranian journal of cancer prevention Iran J Cancer Prev Psychological Predictors of ProstateCancerScreening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy. e4144 Prostatecancer is the fourth most common cancer worldwide and is the second most lethal cancer. The aim of this study (...) was to investigate psychological predictors of prostatecancerscreening behaviors among men over 50 years of age in Hamadan. This cross-sectional study was carried out on 200 men over 50 years of age in Hamadan, west of Iran. Participants were recruited with a cluster sampling method. The subjects completed a self-administered questionnaire including demographic characteristics, prostatecancerscreening behaviors and psychological factors related to prostatecancer. Data was analyzed by SPSS-18 using chi
ProstateCancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. IMPORTANCE: Prostatecancer incidence in men 75 years and older substantially decreased following the 2008 US Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this age group. It is unknown whether incidence has changed since the USPSTF recommendation against screening for all men in May 2012. OBJECTIVE: To examine recent changes (...) in stage-specific prostatecancer incidence and PSAscreening rates following the 2008 and 2012 USPSTF recommendations. DESIGN AND SETTINGS: Ecologic study of age-standardized prostatecancer incidence (newly diagnosed cases/100,000 men aged ≥50 years) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries and PSAscreening rate in the past year among men 50 years and older without a history of prostatecancer who responded
Prostate-Specific Antigen (PSA)?based population screening for prostatecancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis Tawfik A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Tawfik A. Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(11). 2015 Authors' conclusions PSAscreening is associated with significant costs to the health care system when the cost of the PSA test itself is considered in addition to the costs of diagnosis, staging, and treatment of screen-detected PCs. Final publication URL Indexing Status
Prostate-Specific Antigen (PSA)?based population screening for prostatecancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs
Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms (...) of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions Based on the evidence, the following conclusions can be made: There are major harms (unnecessary risks) associated with PSAscreening, including: • harms associated with prostate biopsy • overdiagnosis There are minor harms associated with PSAscreening including: • harms associated with PSA testing PSA-based screening for prostatecancer results in harms related
Factors associated with prostatecancerscreening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model 26120414 2015 06 29 2015 06 29 2017 02 20 7 2 2015 Apr-Jun Electronic physician Electron Physician Factors associated with prostatecancerscreening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model. 1054-62 10.14661/2015.1054-1062 Prostatecancer is one of the most common and lethal cancers in the world. The incidence of prostatecancer has been increasing (...) in recent years. The purpose of this study was to investigate factors associated with prostatecancerscreening behaviors among men over 50 in Fasa, Iran, based on the PRECEDE model. In this cross-sectional study, 400 men over 50 were studied in Fasa, Iran. Data were collected via a questionnaire on demographic characteristics, such as age, number of children, occupation, education, marital status, smoking, and prostatecancerscreening behaviors. Data were analyzed using SPSS software, version 16
Prostate-Specific Antigen?Based Population Screening for ProstateCancerPSA-Based Population Screening for ProstateCancer: OHTAC Recommendation. May 2015; pp. 1–5 Prostate-Specific Antigen (PSA)–Based Population Screening for ProstateCancer: OHTAC Recommendation HEALTH QUALITY ONTARIO ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATION OHTAC recommends against the introduction of a formal, population-based PSAscreening program for prostatecancer in Ontario. BACKGROUND Prostate (...) Population Screening for ProstateCancer: OHTAC Recommendation. May 2015; pp. 1–5 2 average-risk males reduces prostatecancer mortality or overall mortality, increases the detection of prostatecancer, or decreases the rate of aggressive or metastaticcancers? A systematic search of trials published between 2008 and 2013, specifically systematic reviews and randomized controlled trials (RCT) of PSA-based population screening programs, identified 11 reports, including 5 systematic reviews and 6 RCTs